BTIG Reiterates Buy on Rapport Therapeutics, Maintains $65 Price Target

Benzinga · 2d ago
BTIG analyst Kambiz Yazdi reiterates Rapport Therapeutics (NASDAQ:RAPP) with a Buy and maintains $65 price target.